|Bid price||0.00||Open price||0.00|
|Ask price||0.00||Prev close||34.13|
Register now for FREE live Sinclair IS Pharma share prices, Sinclair IS Pharma stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Sinclair IS Pharma Level 2 Data, indepth research tools and investor commentary for Sinclair IS Pharma (SPH) and other London Stock Exchange equities.
Register now for FREE Sinclair IS Pharma share price charts
|Name||Sinclair IS Pharma||Epic||SPH|
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB0033856740|
|Activites||Sinclair IS Pharma plc (formerly Sinclair Pharma plc) is a speciality pharma company providing solutions to treat dermatological diseases through advanced surface technology and innovative delivery systems.||Index||n/a|
|Latest Share Price (p)||0.00||Net Gearing (%)||58.58|
|Market Capitalisation (£m)||175.77||Gross Gearing (%)||63.01|
|Shares in issue (m)||502.20||Debt Ratio||55.77|
|P/E Ratio||-23.33||Debt-to-Equity Ratio||0.74|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||2.70|
|Dividend Yield (%)||0.00||Price to book value||1.66|
|Dividend cover (x)||0.00||ROCE (%)||-3.41|
|Earning per share (p)||-1.50||EPS Growth (%)||-25.00|
|52 week high / low||40.75 / 26.00||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
RNS Number : 3509U Sinclair Pharma PLC 17 January 2017 Hardman Research: Demanding targets exceeded Demanding targets exceeded - Sinclair is a pure-play aesthetics company with a concentrated and highly competitive portfolio of differentiated injectable aesthetics...
Sinclair Pharma is pleased with its 2016 performance, a year when it made excellent progress in its strategy to build a leading global pure-play aesthetics company, says CEO Chris Spooner. "Following the radical re-shaping of the business we are now in a position to deliver significant...
Story provided by StockMarketWire.com
Register now for FREE Sinclair IS Pharma company news
However, you read it, the News today that Dir have been given shares at 1p when the Market mid is 28p looks like something out of the book "They never told such a story, you dreamt it" So just what performance does such largess reward, I wonder? Ah yes, the sp has increased 10-fold, ah so....
News article which appears to have gone unnoticed. From "THIS IS MONEY" website Ubiquitious Warburg Pincus has completed more initial public offerings (IPOs) than any other private equity firm. It is currently putting its considerable weight behind a proposed $1.5bn IPO of Bausch & Lomb,...
Year end 30th June and a trading update out early July. A couple of Funds have been topping up in recent weeks. 62.5% of shares now with investment funds plus another 3.42% with directors.
Register now for FREE Sinclair IS Pharma share price discussions